Endocrinology, 154(8), 2948-2958
Genetic mutations in mitochondrial DNA (mtDNA) have been associated with myopathy, cardiomyopathy, neuropathy, seizures, optic atrophy, strokes, hearing loss, diabetes mellitus, and other clinical features
Clinical Pearl: Ideal Candidates for Combination Therapy Patients that will greatly benefit from L-carnitine adjunctive therapy: Report persistent fatigue despite adequate weight loss on GLP-1 therapy alone Demonstrate signs of muscle loss or declining lean body mass during treatment Have plateaued in their weight loss despite medication optimization Present with metabolic syndrome features beyond elevated BMI (dyslipidemia, insulin resistance) Engage in regular physical activity and seek enhanced athletic performance alongside weight management Monitoring Parameters Regular assessment should include: Weight and body composition measurements every 4-6 weeks Lipid panel and HbA1c at 3-month intervals Liver function tests at baseline and 6 months (L-carnitine may affect hepatic fat metabolism) Patient-reported outcomes: energy levels, GI tolerability, exercise capacity Prescribing Patterns & Updates Growing Interest in Combination Metabolic Therapies Clinical practice patterns indicate increasing adoption of adjunctive therapies alongside GLP-1 medications
Myth: "You can pre-mix a huge batch to last for a month." Terrible idea
Brain 134 , 32223235 (2011)
The nucleus accumbens is considered as a neural interface between motivation and action, having a key role in food intake, sexual behavior, reward-motivated behavior, stress-related behavior and substance dependence (15)
